Current drug therapy for scleroderma and secondary Raynaud's phenomenon: Evidence-based review

Pharmacology, Toxicology and Pharmaceutical Science

• Pharmacotherapy 100%
• Raynaud Phenomenon 100%
• Scleroderma 100%
• Vascular Disease 33%
• Sildenafil 33%
• Phosphodiesterase Inhibitor 33%
• Prostacyclin 33%
• Disease 16%
• Inflammation 16%
• Randomized Controlled Trial 16%
• Symptom 16%
• Injury 16%
• Selective Serotonin Reuptake Inhibitor 16%
• Cyclophosphamide 16%
• Dipeptidyl Carboxypeptidase Inhibitor 16%
• Methotrexate 16%
• Fibrosis 16%
• Calcium Channel Blocker 16%
• Interstitial Lung Disease 16%
• Tissue Injury 16%
• Skin Disease 16%
• Angiotensin Receptor 16%
• Fluoxetine 16%
• Endothelin Receptor Antagonist 16%
• Losartan 16%

Keyphrases

• Angiotensin Receptor Inhibitors 16%

Medicine and Dentistry

• Treatment of Interstitial Lung Disease 16%